Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/102684
Type: | Journal article |
Title: | New-age vaccine adjuvants: friend or foe? A major unsolved challenge in adjuvant development is how to achieve a potent adjuvant effect while avoiding reactogenicity or toxicity |
Author: | Petrovsky, N. Heinzel, S. Honda, Y. Lyons, A.B. |
Citation: | Biopharm International, 2007; 20(8):S24-S33 |
Publisher: | Advanstar Communications |
Issue Date: | 2007 |
ISSN: | 1542-166X |
Statement of Responsibility: | Nikolai Petrovsky, Susanne Heinzel, Yoshikazu Honda and A. Bruce Lyons |
Abstract: | Older vaccines made from live or killed whole organisms were effective, but suffered from high reactogenicity. As vaccine manufacturers developed safer, less reactogenic subunit vaccines, they found that with lower reactogenicity came reduced vaccine effectiveness. Somewhat ironically, the solution proposed to boost immunogenicity in modern vaccines is to add back immune-activating substances such as toll-like receptor agonists - the very same contaminants removed from old-style vaccines. This raises the question of whether the vaccine field is moving forward or backward. We propose that by avoiding adjuvants that work through toll-like receptor (TLR) pathways, and instead focusing on adjuvants stimulating B-and T-cell immunity directly, one can minimize inflammatory cytokine production and consequent reactogenicity. We present data on a polysaccharide-based adjuvant candidate, Advax, that enhances immunogenicity without reactogenicity, suggesting that potent and well-tolerated vaccines for both adult and pediatric use are indeed possible. |
Rights: | © 2007 Advanstar Communications, Inc. |
Published version: | http://www.biopharminternational.com/new-age-vaccine-adjuvants-friend-or-foe |
Appears in Collections: | Aurora harvest 7 Molecular and Biomedical Science publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.